Peptide · Approved

Tesamorelin

A GHRH analog (Egrifta) approved to reduce excess abdominal fat in HIV-associated lipodystrophy.

Key facts

  • Also known as: Egrifta
  • Status: Approved
  • Used for: HIV lipodystrophy (GHRH analog)
  • Natural counterpart: An analog of natural GHRH.
  • Target enzyme / receptor: GHRH receptor (GHRHR) — class B GPCR
  • Signalling pathway: Gαs → cAMP → pituitary growth-hormone release → lipolysis
    In plain terms: Nudges the pituitary to release the body’s own growth hormone.
  • Crystal / cryo-EM structure: Available  PDB 7CZ5 ↗

Status & safety

This is an approved medicine — prescription-only in most countries. Only use it under a licensed clinician, obtained through a pharmacy.

Research & clinical studies

Explore the biochemistry and clinical evidence for Tesamorelin — these open live, date-sorted searches, so they always show the latest.

Read research papers on PubMed ↗

Clinical studies (ClinicalTrials.gov) ↗ Google Scholar ↗ Related guide → All peptides & profiles →

Not medical advice. Chemdu is an educational resource and does not sell, prescribe or supply any peptide. Consult a licensed professional about any medicine or supplement.